Molecular Pathways Related to Short-term Fasting Response
NCT ID: NCT04259879
Last Updated: 2020-02-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
20 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-04-07
Study Completion Date
2016-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will evaluate the effect of short-term fasting (36 hours) in gene expression in blood cells in healthy volunteers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Physiological and Sensory Responses to Prolonged Fasting in Humans
NCT05977569
Fasting
Metabolic Disturbance
Energy Supply; Deficiency
+1 more
UNKNOWN
NA
Fastomics: Metabolic and Therapeutic Effects of Prolonged Fasting
NCT07216989
Insulin Resistance
Fasting
RECRUITING
Physiological Response to 5 Days Fasting
NCT04452916
Healthy
COMPLETED
NA
The Effects of 24-hour Fasting or Carbohydrate Restriction on Postprandial Metabolic Responses
NCT07250191
Glucose and Lipid Metabolism
COMPLETED
NA
Effects of Daily Eating Duration on Health
NCT05964179
Body Weight Maintenance
Nutritional and Metabolic Diseases
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Fasting is a nutritional intervention consisting on the restriction of nutrient intake during a relatively long period of time. It elicits a profound metabolic reprogramming aimed at shifting nutrient supply from external food intake to internal stored nutrients. Periodic activation of this complex response, termed periodic or intermittent fasting (IF), elicits numerous protective effects against aging, metabolic alterations, neurological disorders and cardiovascular health. Short-term fasting is protective in different stress scenarios, including ischemia reperfusion, bouts of inflammation and chemotherapy-induced toxicity, and improves the anti-tumor efficacy of chemotherapy. Although the basic physiology of fasting is well known, the molecular mechanisms underlying its beneficial effects are not yet completely understood.
In mammals, the response to short-term fasting (from 12 to 48 hours) in terms of nutrient mobilization through the bloodstream has been extensively studied. Fasting follows sequential phases, during which nutrients are released from different storing depots. First, glucose is released from glycogen stores in the liver and muscle. Upon depletion of glycogen, two fasting mechanisms are activated: fatty acids are exported from the adipose tissue into the bloodstream in the form of free fatty acids (FFAs), reaching the liver where they are used to produce ketone bodies, a process termed ketogenesis. Also, gluconeogenesis is activated in the liver, generating glucose mainly from glycerol (released during lipolysis) and amino acids, that originate mainly from muscle breakdown. All these physiological responses are tightly regulated by hormonal and molecular mechanisms.
At the hormonal level, fasting induces a decrease in blood insulin, leptin and ghrelin, and an increase in glucagon levels, while blood adiponectin remains unchanged. Also, several signal transduction pathways are affected by fasting. PPARalpha, a nuclear receptor of fatty acids, becomes activated by the fasting-mediated increase in blood Free fatty Acids (FFAs) and triggers the expression of many target genes in several tissues, including blood cells. It has been shown that the Cyclin Dependent Kinase (CDK) inhibitor p21 is highly upregulated during short-term fasting in many mouse tissues. Moreover, it is known that p21-null mice are unable to endure normal periods of fasting and that p21 is required for the full activation of PPARa target genes both in vivo and in isolated hepatocytes.
In the current study, the investigators wanted to study for the first time molecular mechanisms of fasting that still remained unexplored, specially the expression induction of p21 and PPARalpha signalling pathway. For this, the investigators analyzed blood samples from healthy volunteers subjected to 36 hours of fasting, to explore gene expression in Peripheral Blood Mononuclear Cells (PBMCs).
In mammals, the response to short-term fasting (from 12 to 48 hours) in terms of nutrient mobilization through the bloodstream has been extensively studied. Fasting follows sequential phases, during which nutrients are released from different storing depots. First, glucose is released from glycogen stores in the liver and muscle. Upon depletion of glycogen, two fasting mechanisms are activated: fatty acids are exported from the adipose tissue into the bloodstream in the form of free fatty acids (FFAs), reaching the liver where they are used to produce ketone bodies, a process termed ketogenesis. Also, gluconeogenesis is activated in the liver, generating glucose mainly from glycerol (released during lipolysis) and amino acids, that originate mainly from muscle breakdown. All these physiological responses are tightly regulated by hormonal and molecular mechanisms.
At the hormonal level, fasting induces a decrease in blood insulin, leptin and ghrelin, and an increase in glucagon levels, while blood adiponectin remains unchanged. Also, several signal transduction pathways are affected by fasting. PPARalpha, a nuclear receptor of fatty acids, becomes activated by the fasting-mediated increase in blood Free fatty Acids (FFAs) and triggers the expression of many target genes in several tissues, including blood cells. It has been shown that the Cyclin Dependent Kinase (CDK) inhibitor p21 is highly upregulated during short-term fasting in many mouse tissues. Moreover, it is known that p21-null mice are unable to endure normal periods of fasting and that p21 is required for the full activation of PPARa target genes both in vivo and in isolated hepatocytes.
In the current study, the investigators wanted to study for the first time molecular mechanisms of fasting that still remained unexplored, specially the expression induction of p21 and PPARalpha signalling pathway. For this, the investigators analyzed blood samples from healthy volunteers subjected to 36 hours of fasting, to explore gene expression in Peripheral Blood Mononuclear Cells (PBMCs).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Fasting
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
This study was an Interventional study. There were three evaluations: the basal one was an initial evaluation after overnight fasting, the second evaluation 24 hours later (36 hours fasting) and the third one 24 hours post-refeeding.
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fasting
The participants will follow a short-term fasting period for 36 hours
Group Type
EXPERIMENTAL
Fasting
Intervention Type
OTHER
Food intake restriction
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fasting
Food intake restriction
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and women between 18 - 50 years old.
* BMI \>20\<30
* Adequate education level and comprehension of the clinical study
* Willingness to participate in the study as a volunteer and to provide written consent
* BMI \>20\<30
* Adequate education level and comprehension of the clinical study
* Willingness to participate in the study as a volunteer and to provide written consent
Exclusion Criteria
* BMI \<20 (thinness)
* BMI \>30 (obesity)
* Abnormal low glucose levels after fasting
* Having donated blood less than 8 weeks before starting the study
* Subjects who report special discomfort after previous periods of short fasting
* Diagnosis of type 2 Diabetes mellitus (insulin-dependent)
* Dyslipidemia under pharmacological treatment
* High blood pressure under pharmacological treatment
* Dementia, neurological disease or reduction of cognitive function
* Severe illness (hepatic disease, renal disease, etc
* Taking medications that could affect the lipid and glycemic profiles (statins, fibrate, diuretics, corticoids, anti-inflammatory, hypoglycemic or insulin) 30 days before the beginning of the study.
* Taking medications or substances for weight loss management (15 days before the beginning of the study)
* Pregnancy or lactation
* BMI \>30 (obesity)
* Abnormal low glucose levels after fasting
* Having donated blood less than 8 weeks before starting the study
* Subjects who report special discomfort after previous periods of short fasting
* Diagnosis of type 2 Diabetes mellitus (insulin-dependent)
* Dyslipidemia under pharmacological treatment
* High blood pressure under pharmacological treatment
* Dementia, neurological disease or reduction of cognitive function
* Severe illness (hepatic disease, renal disease, etc
* Taking medications that could affect the lipid and glycemic profiles (statins, fibrate, diuretics, corticoids, anti-inflammatory, hypoglycemic or insulin) 30 days before the beginning of the study.
* Taking medications or substances for weight loss management (15 days before the beginning of the study)
* Pregnancy or lactation
Minimum Eligible Age
18 Years
Maximum Eligible Age
50 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centro Nacional de Investigaciones Oncologicas CARLOS III
OTHER
Sponsor Role
collaborator
IMDEA Food
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pablo J Fernandez-Marcos, PhD
Role: PRINCIPAL_INVESTIGATOR
IMDEA Food
Manuel Serrano Marugán, PhD
Role: PRINCIPAL_INVESTIGATOR
Spanish National Cancer Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IMDEA Food
Madrid, , Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Spain
References
Explore related publications, articles, or registry entries linked to this study.
Antoni R, Johnston KL, Collins AL, Robertson MD. Effects of intermittent fasting on glucose and lipid metabolism. Proc Nutr Soc. 2017 Aug;76(3):361-368. doi: 10.1017/S0029665116002986. Epub 2017 Jan 16.
Reference Type
BACKGROUND
Arnason TG, Bowen MW, Mansell KD. Effects of intermittent fasting on health markers in those with type 2 diabetes: A pilot study. World J Diabetes. 2017 Apr 15;8(4):154-164. doi: 10.4239/wjd.v8.i4.154.
Reference Type
BACKGROUND
Gotthardt JD, Verpeut JL, Yeomans BL, Yang JA, Yasrebi A, Roepke TA, Bello NT. Intermittent Fasting Promotes Fat Loss With Lean Mass Retention, Increased Hypothalamic Norepinephrine Content, and Increased Neuropeptide Y Gene Expression in Diet-Induced Obese Male Mice. Endocrinology. 2016 Feb;157(2):679-91. doi: 10.1210/en.2015-1622. Epub 2015 Dec 14.
Reference Type
BACKGROUND
Halberg N, Henriksen M, Soderhamn N, Stallknecht B, Ploug T, Schjerling P, Dela F. Effect of intermittent fasting and refeeding on insulin action in healthy men. J Appl Physiol (1985). 2005 Dec;99(6):2128-36. doi: 10.1152/japplphysiol.00683.2005. Epub 2005 Jul 28.
Reference Type
BACKGROUND
Mattson MP, Longo VD, Harvie M. Impact of intermittent fasting on health and disease processes. Ageing Res Rev. 2017 Oct;39:46-58. doi: 10.1016/j.arr.2016.10.005. Epub 2016 Oct 31.
Reference Type
BACKGROUND
Varady KA, Bhutani S, Church EC, Klempel MC. Short-term modified alternate-day fasting: a novel dietary strategy for weight loss and cardioprotection in obese adults. Am J Clin Nutr. 2009 Nov;90(5):1138-43. doi: 10.3945/ajcn.2009.28380. Epub 2009 Sep 30.
Reference Type
BACKGROUND
Vasconcelos AR, Yshii LM, Viel TA, Buck HS, Mattson MP, Scavone C, Kawamoto EM. Intermittent fasting attenuates lipopolysaccharide-induced neuroinflammation and memory impairment. J Neuroinflammation. 2014 May 6;11:85. doi: 10.1186/1742-2094-11-85.
Reference Type
BACKGROUND
Tinkum KL, Stemler KM, White LS, Loza AJ, Jeter-Jones S, Michalski BM, Kuzmicki C, Pless R, Stappenbeck TS, Piwnica-Worms D, Piwnica-Worms H. Fasting protects mice from lethal DNA damage by promoting small intestinal epithelial stem cell survival. Proc Natl Acad Sci U S A. 2015 Dec 22;112(51):E7148-54. doi: 10.1073/pnas.1509249112. Epub 2015 Dec 7.
Reference Type
BACKGROUND
Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY). 2009 Dec 31;1(12):988-1007. doi: 10.18632/aging.100114.
Reference Type
BACKGROUND
Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo VD. Fasting and differential chemotherapy protection in patients. Cell Cycle. 2010 Nov 15;9(22):4474-6. doi: 10.4161/cc.9.22.13954. Epub 2010 Nov 15.
Reference Type
BACKGROUND
Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, Pistoia V, Wei M, Hwang S, Merlino A, Emionite L, de Cabo R, Longo VD. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012 Mar 7;4(124):124ra27. doi: 10.1126/scitranslmed.3003293. Epub 2012 Feb 8.
Reference Type
BACKGROUND
Di Biase S, Lee C, Brandhorst S, Manes B, Buono R, Cheng CW, Cacciottolo M, Martin-Montalvo A, de Cabo R, Wei M, Morgan TE, Longo VD. Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity. Cancer Cell. 2016 Jul 11;30(1):136-146. doi: 10.1016/j.ccell.2016.06.005.
Reference Type
BACKGROUND
Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, Senovilla L, Marino G, Aranda F, Durand S, Sica V, Chery A, Lachkar S, Sigl V, Bloy N, Buque A, Falzoni S, Ryffel B, Apetoh L, Di Virgilio F, Madeo F, Maiuri MC, Zitvogel L, Levine B, Penninger JM, Kroemer G. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell. 2016 Jul 11;30(1):147-160. doi: 10.1016/j.ccell.2016.05.016.
Reference Type
BACKGROUND
Ruderman NB. Muscle amino acid metabolism and gluconeogenesis. Annu Rev Med. 1975;26:245-58. doi: 10.1146/annurev.me.26.020175.001333. No abstract available.
Reference Type
BACKGROUND
Cahill GJ Jr, Owen OE, Morgan AP. The consumption of fuels during prolonged starvation. Adv Enzyme Regul. 1968;6:143-50. doi: 10.1016/0065-2571(68)90011-3. No abstract available.
Reference Type
BACKGROUND
Nuttall FQ, Almokayyad RM, Gannon MC. Comparison of a carbohydrate-free diet vs. fasting on plasma glucose, insulin and glucagon in type 2 diabetes. Metabolism. 2015 Feb;64(2):253-62. doi: 10.1016/j.metabol.2014.10.004. Epub 2014 Oct 8.
Reference Type
BACKGROUND
Nuttall FQ, Almokayyad RM, Gannon MC. The ghrelin and leptin responses to short-term starvation vs a carbohydrate-free diet in men with type 2 diabetes; a controlled, cross-over design study. Nutr Metab (Lond). 2016 Jul 22;13:47. doi: 10.1186/s12986-016-0106-x. eCollection 2016.
Reference Type
BACKGROUND
Merl V, Peters A, Oltmanns KM, Kern W, Born J, Fehm HL, Schultes B. Serum adiponectin concentrations during a 72-hour fast in over- and normal-weight humans. Int J Obes (Lond). 2005 Aug;29(8):998-1001. doi: 10.1038/sj.ijo.0802971.
Reference Type
BACKGROUND
Bouwens M, Afman LA, Muller M. Fasting induces changes in peripheral blood mononuclear cell gene expression profiles related to increases in fatty acid beta-oxidation: functional role of peroxisome proliferator activated receptor alpha in human peripheral blood mononuclear cells. Am J Clin Nutr. 2007 Nov;86(5):1515-23. doi: 10.1093/ajcn/86.5.1515.
Reference Type
BACKGROUND
Lopez-Guadamillas E, Fernandez-Marcos PJ, Pantoja C, Munoz-Martin M, Martinez D, Gomez-Lopez G, Campos-Olivas R, Valverde AM, Serrano M. p21Cip1 plays a critical role in the physiological adaptation to fasting through activation of PPARalpha. Sci Rep. 2016 Oct 10;6:34542. doi: 10.1038/srep34542.
Reference Type
BACKGROUND
Prokesch A, Graef FA, Madl T, Kahlhofer J, Heidenreich S, Schumann A, Moyschewitz E, Pristoynik P, Blaschitz A, Knauer M, Muenzner M, Bogner-Strauss JG, Dohr G, Schulz TJ, Schupp M. Liver p53 is stabilized upon starvation and required for amino acid catabolism and gluconeogenesis. FASEB J. 2017 Feb;31(2):732-742. doi: 10.1096/fj.201600845R. Epub 2016 Nov 3.
Reference Type
BACKGROUND
Tinkum KL, White LS, Marpegan L, Herzog E, Piwnica-Worms D, Piwnica-Worms H. Forkhead box O1 (FOXO1) protein, but not p53, contributes to robust induction of p21 expression in fasted mice. J Biol Chem. 2013 Sep 27;288(39):27999-8008. doi: 10.1074/jbc.M113.494328. Epub 2013 Aug 5.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IMD PI0025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluation of a Fasting Mimicking Diet
NCT04150159
COMPLETED
NA
Metabolic Effects of Morning 16/8 Fasting
NCT04293003
COMPLETED
NA
Energy -Sensing Metabolites in Caloric Restriction
NCT05031572
COMPLETED
NA
A Retrospective and Prospective Cohort Study of the 21-day Fasting-like Diet in Patients With Metabolic and Autoimmune Diseases
NCT03193177
COMPLETED
Fasting-mimicking Diet and Longevity Diet, Body Composition and Aging
NCT05698654
UNKNOWN
NA
The Fasting II Study
NCT01792986
COMPLETED
NA
Prolonged Daily Fasting as a Viable Alternative to Caloric Restriction in At-Risk Obese Humans
NCT04259632
COMPLETED
NA
Effects of Intermittent Fasting on Insulin Resistance, Cardiac Metabolism, and Cerebral Perfusion
NCT05181267
ACTIVE_NOT_RECRUITING
NA
Role of Leptin in the Neuroendocrine and Immune Response to Fasting
NCT00140231
COMPLETED
PHASE1/PHASE2
Short Term Intermittent Fasting and Mediterranean Diet
NCT02148458
COMPLETED
NA
Effect of a Mixed Macronutritional Meal With Medium Chain Triglycerides on the Oxidation of Postprandial Macronutrients
NCT04321018
UNKNOWN
NA
Effects of Dietary Manipulation on Metabolism in Healthy Adults
NCT00476125
COMPLETED
NA
Clinical Feasibility and Efficacy of Intermittent Use of a Fasting Mimicking Diet in the Treatment of Type 2 Diabetes
NCT03811587
COMPLETED
NA
Time Course and Nature of Nutrient Sensing During Fasting in Humans
NCT01387919
COMPLETED
NA
Intermittent Fasting for the Treatment of Type 2 Diabetes Mellitus
NCT05860413
COMPLETED
NA
Long-term Resveratrol and Metabolism
NCT02565979
COMPLETED
NA
The Relationship Between Body Composition and Growth Hormone, SIRT Signaling, Protein Turnover and Insulin Sensitivity
NCT01299831
COMPLETED
NA
Effect of Fasting and Refeeding on T-cell Fate
NCT02719899
COMPLETED
Ramadan Fasting Effects in Patients With Cardiovascular Risk Factors
NCT02720133
COMPLETED
Effect of Intermittent Fasting (Month of Ramadan) on Health
NCT05571891
COMPLETED
Liver Glycogen Dynamics
NCT04510155
COMPLETED
NA
Expression of Longevity Genes in Response to Extended Fasting
NCT01059760
COMPLETED
NA
Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects
NCT01257841
COMPLETED
NA
Short Term Intermittent Fasting and Insulin Resistance
NCT02420054
UNKNOWN
NA